{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:36:20Z","timestamp":1787027780894,"version":"build-2736575974"},"reference-count":59,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K08304"],"award-info":[{"award-number":["17K08304"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K07194"],"award-info":[{"award-number":["20K07194"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K16632"],"award-info":[{"award-number":["17K16632"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K09476"],"award-info":[{"award-number":["19K09476"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K17739"],"award-info":[{"award-number":["17K17739"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K17955"],"award-info":[{"award-number":["20K17955"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Multimodal therapy including surgery, radiation treatment, and temozolomide (TMZ) is performed on glioblastoma (GBM). However, the prognosis is still poor and there is an urgent need to develop effective treatments to improve survival. Molecular biological analysis was conducted to examine the signal activation patterns in GBM specimens and remains an open problem. Advanced macrolides, such as azithromycin, reduce the phosphorylation of p70 ribosomal protein S6 kinase (p70S6K), a downstream mammalian target of rapamycin (mTOR) effector, and suppress the proliferation of T-cells. We focused on its unique profile and screened for the antitumor activity of approved macrolide antibiotics. Clindamycin (CLD) reduced the viability of GBM cells in vitro. We assessed the effects of the candidate macrolide on the mTOR pathway through Western blotting. CLD attenuated p70S6K phosphorylation in a dose-dependent manner. These effects on GBM cells were enhanced by co-treatment with TMZ. Furthermore, CLD inhibited the expression of the O6-methylguanine-DNA methyltransferase (MGMT) protein in cultured cells. In the mouse xenograft model, CLD and TMZ co-administration significantly suppressed the tumor growth and markedly decreased the number of Ki-67 (clone MIB-1)-positive cells within the tumor. These results suggest that CLD suppressed GBM cell growth by inhibiting mTOR signaling. Moreover, CLD and TMZ showed promising synergistic antitumor activity.<\/jats:p>","DOI":"10.3390\/cancers14030770","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T05:42:33Z","timestamp":1643866953000},"page":"770","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Novel Repositioning Therapy for Drug-Resistant Glioblastoma: In Vivo Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide"],"prefix":"10.3390","volume":"14","author":[{"given":"Takeyoshi","family":"Eda","sequence":"first","affiliation":[{"name":"Division of Pharmacy, Medical and Dental Hospital, Niigata University, Niigata 951-8520, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9151-8184","authenticated-orcid":false,"given":"Masayasu","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Kanemaru","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9474-2483","authenticated-orcid":false,"given":"Jun","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5887-7153","authenticated-orcid":false,"given":"Jotaro","family":"On","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Oishi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6122-939X","authenticated-orcid":false,"given":"Nobuyuki","family":"Takei","sequence":"additional","affiliation":[{"name":"Department of Brain Tumor Biology, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiko","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3098-8323","authenticated-orcid":false,"given":"Manabu","family":"Natsumeda","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"},{"name":"Department of Brain Tumor Biology, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1073\/pnas.91.16.7727","article-title":"A mutant epidermal growth factor receptor common in human gliomaconfersenhancedtumorigenicity","volume":"91","author":"Nishikawa","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fonc.2015.00005","article-title":"Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma","volume":"5","author":"Padfield","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1200\/JCO.2009.21.9832","article-title":"Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas","volume":"27","author":"Sanson","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.1158\/0008-5472.CAN-04-1337","article-title":"Genetic Pathways to Glioblastoma","volume":"64","author":"Ohgaki","year":"2004","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455, 1061\u20131068.","DOI":"10.1038\/nature07385"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1750-3639.2003.tb00481.x","article-title":"Genetic Alterations and Aberrant Expression of Genes Related to the Phosphatidyl-Inositol-3\u2032-Kinase\/Protein Kinase B (Akt) Signal TransductionPathway in Glioblastomas","volume":"13","author":"Knobbe","year":"2003","journal-title":"Brain Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00228-011-1161-x","article-title":"Macrolides: From in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases","volume":"68","author":"Zarogoulidis","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/CMR.00078-09","article-title":"Mechanisms of action and clinical application of macrolides as immunomodulatory medications","volume":"23","author":"Kanoh","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.pharmthera.2007.11.001","article-title":"Macrolide antibiotics as immunomodulatory medications: Proposed mechanisms of action","volume":"117","author":"Shinkai","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1164\/ajrccm.157.6.9710075","article-title":"Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin","volume":"157","author":"Kudoh","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7438","DOI":"10.1038\/srep07438","article-title":"Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity","volume":"4","author":"Ratzinger","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/neuonc\/noq052","article-title":"mTOR signaling in glioblastoma: Lessons learned from bench to bedside","volume":"12","author":"Akhavan","year":"2010","journal-title":"Neuro Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1101\/gad.1596707","article-title":"Malignant astrocytic glioma: Genetics, biology, and paths to treatment","volume":"21","author":"Furnari","year":"2007","journal-title":"Genes Dev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s40478-019-0774-7","article-title":"Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: Establishment and xenograft of a cell line to predict clinical efficacy","volume":"7","author":"Kanemaru","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1124\/mol.106.033167","article-title":"Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: Role of Akt and extracellular signal-regulated kinase signaling pathways","volume":"72","author":"Aoki","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1006\/bbrc.1998.9671","article-title":"Characterization of the Phosphoproteins and Protein Kinase Activity in mTOR Immunoprecipitates","volume":"252","author":"Nishiuma","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"42818","DOI":"10.1074\/jbc.M103237200","article-title":"Brain-derived neurotrophic factor enhances neuronal translation by activating multiple initiation processes: Comparison with the effects of insulin","volume":"276","author":"Takei","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/bpa.12343","article-title":"Targeting Notch Signaling and Autophagy Increases Cytotoxicity in Glioblastoma Neurospheres","volume":"26","author":"Natsumeda","year":"2016","journal-title":"Brain Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1002\/stem.2380","article-title":"Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide-Resistant Glioblastoma-Initiating Cells","volume":"34","author":"Tsukamoto","year":"2016","journal-title":"Stem Cells"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13041-021-00755-0","article-title":"Phosphorylation of GAP-43 T172 is a molecular marker of growing axons in a wide range of mammals including primates","volume":"14","author":"Okada","year":"2021","journal-title":"Mol. Brain"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/neup.12196","article-title":"Immunohistochemical profiles of IDH1, MGMT and P53: Practical significance for prognostication of patients with diffuse gliomas","volume":"35","author":"Ogura","year":"2015","journal-title":"Neuropathology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/neuonc\/nov316","article-title":"Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma","volume":"18","author":"Abedalthagafi","year":"2016","journal-title":"Neuro Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.canlet.2017.04.019","article-title":"The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma","volume":"400","author":"Miyahara","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1158\/1078-0432.CCR-13-0527","article-title":"The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas","volume":"19","author":"Gini","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"14484","DOI":"10.1074\/jbc.273.23.14484","article-title":"Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism","volume":"273","author":"Hara","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fnmol.2014.00028","article-title":"mTOR signaling and its roles in normal and abnormal brain development","volume":"7","author":"Takei","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1038\/sj.onc.1209883","article-title":"Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases","volume":"25","author":"Mayer","year":"2006","journal-title":"Oncogene"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1158\/0008-5472.CAN-04-3640","article-title":"Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase\/protein kinase B inhibitors","volume":"65","author":"Takeuchi","year":"2005","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt","volume":"66","author":"Rojo","year":"2006","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: Are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1158\/1535-7163.MCT-09-0160","article-title":"NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas","volume":"8","author":"Liu","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/neuonc\/noq193","article-title":"Inhibition of PI3K\/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide","volume":"13","author":"Prasad","year":"2011","journal-title":"Neuro Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/jnc.14899","article-title":"Synergistic growth inhibition mediated by dual PI3K\/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models","volume":"153","author":"Weller","year":"2020","journal-title":"J. Neurochem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1383-5742(00)00017-X","article-title":"Repair of O6-alkylguanine by alkyltransferases","volume":"462","author":"Pegg","year":"2000","journal-title":"Mutat. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s11060-018-2831-7","article-title":"JCOG0911 INTEGRA study: A randomized screening phase II trial of interferonbeta plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma","volume":"138","author":"Wakabayashi","year":"2018","journal-title":"J. Neurooncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.molcel.2010.09.028","article-title":"Translational regulation of gene expression during conditions of cell stress","volume":"40","author":"Spriggs","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"8750","DOI":"10.1073\/pnas.1219232110","article-title":"Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas","volume":"110","author":"Sievert","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/neuonc\/noz230","article-title":"Synergistic activity of mTORC1\/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity","volume":"22","author":"Arnold","year":"2020","journal-title":"Neuro Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Conciatori, F., Ciuffreda, L., Bazzichetto, C., Falcone, I., Pilotto, S., Bria, E., Cognetti, F., and Milella, M. (2018). mTOR Cross-Talk in Cancer and Potential for Combination Therapy. Cancers, 10.","DOI":"10.3390\/cancers10010023"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation","volume":"36","author":"Mendoza","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"ref_48","first-page":"51","article-title":"Basic and clinical studies on clindamycin for intravenous injection","volume":"30","author":"Imaoka","year":"1977","journal-title":"Jpn. J. Antibiot."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1128\/AAC.45.9.2638-2642.2001","article-title":"Pretreatment of mice with clindamycin improves survival of endotoxic shock by modulating the release of inflammatory cytokines","volume":"45","author":"Hirata","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00381-012-1732-x","article-title":"The effects of temozolomide delivered by prolonged intracerebral microinfusion against the rat brainstem GBM allograft model","volume":"28","author":"Yoshimura","year":"2012","journal-title":"Childs Nerv. Syst."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3171\/2011.2.PEDS10407","article-title":"Regression of recurrent glioblastoma infiltrating the brainstem after convection-enhanced delivery of nimustine hydrochloride","volume":"7","author":"Saito","year":"2011","journal-title":"J. Neurosurg. Pediatr."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1215\/15228517-2007-052","article-title":"New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163","volume":"10","author":"Hashizume","year":"2008","journal-title":"Neuro Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11060-017-2681-8","article-title":"New therapeutic approaches for brainstem tumors: A comparison of delivery routes using nanoliposomal irinotecan in an animal model","volume":"136","author":"Louis","year":"2018","journal-title":"J. Neurooncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4161\/cbt.11.5.14410","article-title":"A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors","volume":"11","author":"Lim","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Wei, K.C., Chu, P.C., Wang, H.Y., Huang, C.Y., Chen, P.Y., Tsai, H.C., Lu, Y.J., Lee, P.Y., Tseng, I.C., and Feng, L.Y. (2013). Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: A preclinical study. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0058995"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: Identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"111728","DOI":"10.18632\/oncotarget.22904","article-title":"Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug","volume":"8","author":"Dong","year":"2017","journal-title":"Oncotarget"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nm.3855","article-title":"Functionally defined therapeutic targets in diffuse intrinsic pontine glioma","volume":"21","author":"Grasso","year":"2015","journal-title":"Nat. Med."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Pfab, C., Schnobrich, L., Eldnasoury, S., Gessner, A., and El-Najjar, N. (2021). Repurposing of Antimicrobial Agents for Cancer Therapy: What Do We Know?. Cancers, 13.","DOI":"10.3390\/cancers13133193"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/770\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:12:52Z","timestamp":1760134372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":59,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14030770"],"URL":"https:\/\/doi.org\/10.3390\/cancers14030770","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202112.0396.v1","asserted-by":"object"}]},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]}}}